Discover the latest research on Ozempic and other GLP-1 medications, including potential uses in treating Alzheimer's and opioid and alcohol use disorders.

This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ...

THEY are the drugs that have taken 2024 by storm – and now weight loss injections could come with yet more added benefits. So-called skinny jabs – that were initially designed as ...

Issued on behalf of PlantX Life Inc. VANCOUVER, BC, Oct. 24, 2024 /PRNewswire/ -- USA News Group News Commentary – With more than 100 million Americans struggling with obesity, and obesity rates ...

The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk’s Wegovy or similar GLP-1 ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced that dosing has begun, for human pilot study #3, investigating a DehydraTECH-processed version of the dual action ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the ...

In announcing the results, Novo Nordisk said Rybelsus, an oral glucagon-like peptide-1 (GLP-1) receptor agonist already ...

When you're taking GLP-1 medications for weight loss, it's easy for nutrition to get overlooked because while semaglutide ...